Literature DB >> 31916129

The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study.

Hussein Kadhem Al-Hakeim1, Abbas F Almulla2, Michael Maes3,4,5.   

Abstract

No studies have examined the immune fingerprint of major neurocognitive psychosis (MNP) or deficit schizophrenia using M1 macrophage cytokines in combination with chemokines such as CCL2 and CCL11. The present study delineated the neuroimmune fingerprint of MNP by analyzing plasma levels of IL-1β, sIL-1RA, TNFα, sTNFR1, sTNFR2, CCL2, and CCL11 in 120 MNP versus 54 healthy controls in association with neurocognitive scores (as assessed with the Brief Assessment of Cognition in Schizophrenia) and PHEMN (psychotic, hostility, excitation, mannerism and negative) symptoms. MNP was best predicted by a combination of CCL11, TNFα, IL-1β, and sIL-1RA which yielded a bootstrapped (n = 2000) area under the receiver operating curve of 0.985. Composite scores reflecting M1 macrophage activity and neurotoxic potential including effects of CCL11 and CCL2 were significantly increased in MNP. A large part of the variance in PHEM (38.4-52.6%) and negative (65.8-74.4%) symptoms were explained by combinations of immune markers whereby CCL11 was the most important. The same markers explained a large part of the variance in the Mini-Mental State examination, list learning, digit sequencing task, category instances, controlled word association, symbol coding, and Tower of London. Partial least squares analysis showed that 72.7% of the variance in overall severity of schizophrenia was explained by the regression on IL-1β, sIL-1RA, CCL11, TNFα, and education. It is concluded that the combination of the abovementioned markers defines MNP as a distinct neuroimmune disorder and that increased immune neurotoxicity determines memory and executive impairments and PHEMN symptoms as well.

Entities:  

Keywords:  Cognition; Cytokine; Deficit schizophrenia; Immunological biomarkers; Machine learning

Mesh:

Substances:

Year:  2020        PMID: 31916129     DOI: 10.1007/s12640-019-00112-z

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  64 in total

Review 1.  Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression.

Authors:  George Anderson; Michael Maes
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-07-16       Impact factor: 5.067

2.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

3.  The macrophage-T-lymphocyte theory of schizophrenia: additional evidence.

Authors:  R S Smith; M Maes
Journal:  Med Hypotheses       Date:  1995-08       Impact factor: 1.538

4.  The Schedule for the Deficit syndrome: an instrument for research in schizophrenia.

Authors:  B Kirkpatrick; R W Buchanan; P D McKenney; L D Alphs; W T Carpenter
Journal:  Psychiatry Res       Date:  1989-11       Impact factor: 3.222

5.  Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs.

Authors:  M Maes; J Delange; R Ranjan; H Y Meltzer; R Desnyder; W Cooremans; S Scharpé
Journal:  Psychiatry Res       Date:  1997-01-15       Impact factor: 3.222

6.  Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis.

Authors:  Subhajit Dasgupta; Malabendu Jana; Xiaojuan Liu; Kalipada Pahan
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

Review 7.  Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?

Authors:  Michael Maes; George Anderson; Marta Kubera; Michael Berk
Journal:  Expert Opin Ther Targets       Date:  2014-02-19       Impact factor: 6.902

8.  Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.

Authors:  Stéphane Potvin; Emmanuel Stip; Amir A Sepehry; Alain Gendron; Ramatoulaye Bah; Edouard Kouassi
Journal:  Biol Psychiatry       Date:  2007-11-19       Impact factor: 13.382

9.  Systemic TNF-α produces acute cognitive dysfunction and exaggerated sickness behavior when superimposed upon progressive neurodegeneration.

Authors:  Edel Hennessy; Shane Gormley; Ana Belen Lopez-Rodriguez; Caoimhe Murray; Carol Murray; Colm Cunningham
Journal:  Brain Behav Immun       Date:  2016-09-12       Impact factor: 7.217

10.  MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes.

Authors:  Brianne M Bettcher; Ryan Fitch; Matthew J Wynn; Matthew A Lalli; Jonathan Elofson; Laura Jastrzab; Laura Mitic; Zachary A Miller; Gil D Rabinovici; Bruce L Miller; Aimee W Kao; Kenneth S Kosik; Joel H Kramer
Journal:  Alzheimers Dement (Amst)       Date:  2016-06-22
View more
  10 in total

1.  The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments.

Authors:  Abbas F Almulla; Asara Vasupanrajit; Chavit Tunvirachaisakul; Hussein K Al-Hakeim; Marco Solmi; Robert Verkerk; Michael Maes
Journal:  Mol Psychiatry       Date:  2022-04-14       Impact factor: 15.992

Review 2.  Recent advancements in biomarker research in schizophrenia: mapping the road from bench to bedside.

Authors:  Shivangi Patel; Dilip Sharma; Ankit Uniyal; Anagha Gadepalli; Vinod Tiwari
Journal:  Metab Brain Dis       Date:  2022-03-03       Impact factor: 3.655

3.  Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates.

Authors:  Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Amer Alhaideri; Michael Maes
Journal:  Metab Brain Dis       Date:  2020-09-23       Impact factor: 3.584

4.  High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.

Authors:  Arafat Hussein Al-Dujaili; Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Michael Maes
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

5.  In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy.

Authors:  Hussein Kadhem Al-Hakeim; Rana Fadhil Mousa; Arafat Hussein Al-Dujaili; Michael Maes
Journal:  Metab Brain Dis       Date:  2021-02-13       Impact factor: 3.584

Review 6.  The Role of CCL2/CCR2 Axis in Cerebral Ischemia-Reperfusion Injury and Treatment: From Animal Experiments to Clinical Trials.

Authors:  Huixia Geng; Luna Chen; Jing Tang; Yi'ang Chen; Lai Wang
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

7.  The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis.

Authors:  Hussein Kadhem Al-Hakeim; Ali Fattah Al-Musawi; Abbas Al-Mulla; Arafat Hussein Al-Dujaili; Monojit Debnath; Michael Maes
Journal:  PLoS One       Date:  2022-10-18       Impact factor: 3.752

8.  Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity.

Authors:  Michael Maes; Sunee Sirivichayakul; Andressa Keiko Matsumoto; Annabel Maes; Ana Paula Michelin; Laura de Oliveira Semeão; João Victor de Lima Pedrão; Estefania G Moreira; Decio S Barbosa; Michel Geffard; Andre F Carvalho; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2020-02-10       Impact factor: 5.590

Review 9.  The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines.

Authors:  Tomasz Boczek; Joanna Mackiewicz; Marta Sobolczyk; Julia Wawrzyniak; Malwina Lisek; Bozena Ferenc; Feng Guo; Ludmila Zylinska
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

10.  Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self.

Authors:  Michael Maes
Journal:  J Pers Med       Date:  2022-03-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.